BioXcel Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2017-01-01

Employees: 74

Market Cap: $26.8M

Website: http://www.bioxceltherapeutics.com

Introduction: BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Clinical Trials

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Phase 4

Completed

Conditions: Bipolar Disorder
Schizophrenia
Agitation,Psychomotor
Schizophreniform Disorders
Schizo Affective Disorder

Interventions: Drug: Sublingual film containing Igalmi

First Posted Date: 2023-09-18

Last Posted Date: 2024-05-13

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 23

Registration Number: NCT06041646

Locations: 🇺🇸
BioXcel Clinical Research Site, Rogers, Arkansas, United States

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Phase 3

Terminated

Conditions: Agitation
Dementia

Interventions: Drug: BXCL501
Drug: Matching Placebo

First Posted Date: 2022-12-27

Last Posted Date: 2023-12-11

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 13

Registration Number: NCT05665088

Locations: 🇺🇸
BioXcel Clinical Research Site, Toms River, New Jersey, United States

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Phase 3

Recruiting

Conditions: Agitation,Psychomotor
Bipolar I Disorder
Bipolar II Disorder
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorders

Interventions: Drug: BXCL501
Drug: Matching Placebo

First Posted Date: 2022-12-20

Last Posted Date: 2024-12-24

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 450

Registration Number: NCT05658510

Locations: 🇺🇸
BioXcel Clinical Research Site 112, Little Rock, Arkansas, United States
🇺🇸
BioXcel Clinical Research Site 113, Bellflower, California, United States
🇺🇸
BioXcel Clinical Research Site 128, Cerritos, California, United States

and more 22 locations

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

Phase 2

Withdrawn

Conditions: Delirium
Agitation

Interventions: Drug: BXCL501
Drug: Placebo film

First Posted Date: 2022-04-06

Last Posted Date: 2022-04-06

Lead Sponsor: BioXcel Therapeutics Inc

Registration Number: NCT05313386

Locations: 🇺🇸
BioXcel Clinical Research Site, Nashville, Tennessee, United States

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Phase 2

Terminated

Conditions: Agitation
Dementia

Interventions: Drug: BXCL501
Drug: Placebo film

First Posted Date: 2022-03-11

Last Posted Date: 2023-08-25

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 5

Registration Number: NCT05276830

Locations: 🇺🇸
BioXcel Clinical Research Site, Toms River, New Jersey, United States
🇺🇸
Bioxcel Clinical Research Site, Springfield, Massachusetts, United States

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

Phase 3

Completed

Conditions: Agitation
Dementia

Interventions: Drug: BXCL501
Drug: Matching Placebo

First Posted Date: 2022-03-09

Last Posted Date: 2023-12-11

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 151

Registration Number: NCT05271552

Locations: 🇺🇸
BioXcel Clinical Research Site, Toms River, New Jersey, United States

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Phase 1

Recruiting

Conditions: Bipolar Disorder I
Schizophreniform; Schizophrenic
Bipolar Disorder II
Schizophrenia
Schizo-Affective Disorder

Interventions: Drug: BXCL501 80 Micrograms
Drug: BXCL501 120 Micrograms
Drug: BXCL501 60 Micrograms
Drug: Placebo Film

First Posted Date: 2021-08-27

Last Posted Date: 2024-11-12

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 140

Registration Number: NCT05025605

Locations: 🇺🇸
Bioxcel Clinical Research Site, Decatur, Georgia, United States
🇺🇸
BioXcel Clinical Research Site, DeSoto, Texas, United States

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

Phase 1

Completed

Conditions: Opioid Withdrawal

Interventions: Drug: Dexmedetomidine
Drug: Placebo

First Posted Date: 2020-07-14

Last Posted Date: 2023-10-26

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 225

Registration Number: NCT04470050

Locations: 🇺🇸
BioXcel Clinical Research Site, New York, New York, United States

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

Phase 3

Completed

Conditions: Agitation Associated With Bipolar Disorder
Agitation,Psychomotor
Bipolar Disorder

Interventions: Drug: Sublingual film containing Dexmedetomidine (BXCL501)
Drug: Placebo Film

First Posted Date: 2020-02-19

Last Posted Date: 2023-09-11

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 380

Registration Number: NCT04276883

Locations: 🇺🇸
BioXcel Clinical Research Site, Richardson, Texas, United States

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

Phase 3

Completed

Conditions: Agitation
Schizophrenia
Schizo Affective Disorder
Schizoaffective Disorder
Schizophreniform Disorders

Interventions: Drug: Sublingual film containing dexmedetomidine (BXCL501)
Drug: Placebo Film

First Posted Date: 2020-02-13

Last Posted Date: 2023-06-18

Lead Sponsor: BioXcel Therapeutics Inc

Target Recruit Count: 380

Registration Number: NCT04268303

Locations: 🇺🇸
BioXcel Clinical Research Site, Richardson, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy